An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia

References

• Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319(15):1566–1579.
   PubMed Web of Science ®Google Scholar
• Ueshima H, Kasagi F, Kodama K, et al. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J. 2006;70(10):1249–1255.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Ohashi Y, Nakaya N, et al. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circ J. 2008;72(10):1569–1575.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435.
   PubMed Web of Science ®Google Scholar
• Mirjanic-Azaric B, Rizzo M, Jürgens G, et al. Atorvastatin treatment increases plasma bilirubin but not HMOX1 expression in stable angina patients. Scand J Clin Lab Invest. 2015;75:382–389.
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Berthold HK, Gylling H, et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis. 2008;198:198–207.
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein level. Circulation. 2001;103(15):1933–1935.
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64–70.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959–1965.
   PubMed Web of Science ®Google Scholar
• Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002;106(12):1447–1452.
   PubMed Web of Science ®Google Scholar
• Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108(13):1560–1566.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Sugiyama S, Kugiyama K, et al. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol. 2005;46(11):2022–2030.
   PubMed Web of Science ®Google Scholar
• Nohara R, Daida H, Hata M, et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study. Circ J. 2012;76(1):221–229.
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European society of cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636–648.
   PubMed Web of Science ®Google Scholar
• Agabiti Rosei E, Salvetti M. Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk. High Blood Press Cardiovasc Prev. 2016;23(3):217–230.
   PubMed Web of Science ®Google Scholar
• Valerio MG, Velayati A, Jain D, et al. Promising new therapies for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2016;16(5):609–618.
   PubMed Web of Science ®Google Scholar
• Holecki M, Handzlik-Orlik G, Almgren-Rachtan A, et al. The decreased achievement of therapeutic goal in lipid lowering therapy in obese and diabetic patients in Poland. Pharmacol Rep. 2017;69(1):6–12.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395–2410.
   PubMed Web of Science ®Google Scholar
• Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2 investigators lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120(1):28–34.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467–494.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;2019:ehz455.
   Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1046–e1081.
   PubMed Web of Science ®Google Scholar
• Alshamiri M, Ghanaim MMA, Barter P, et al. Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. Int J Gen Med. 2018;11:313–322.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87.
   PubMed Web of Science ®Google Scholar
• Nusbaumer B, Glechner A, Kaminski-Hartenthaler A, et al. Ezetimibe-statin combination therapy. Efficacy and safety as compared with statin monotherapy — a systematic review. Dtsch Arztebl Int. 2016;113(26):445–453.
   PubMed Web of Science ®Google Scholar
• Foody JAM, Toth PP, Tomassini JE, et al. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc Health Risk Manag. 2013;9:719–727.
   PubMedGoogle Scholar
• Cortese F, Gesualdo M, Cortese A, et al. Rosuvastatin: beyond the cholesterol-lowering effect. Pharmacol Res. 2016;107:1–18.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K, Spinas GA, et al. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance? Int J Clin Pract. 2009;63:478–485.
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152–160.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69–76.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins – clinical evidence. Curr Pharm Des. 2009;15:479–489.
   PubMed Web of Science ®Google Scholar
• Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203:325–330.
   PubMed Web of Science ®Google Scholar
• Kini AS, Baber U, Kovacic J, et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW Trial (Reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62(1):21–29.
   PubMed Web of Science ®Google Scholar
• Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54(5):472–477.
   PubMed Web of Science ®Google Scholar
• Brault M, Ray J, Gomez YH, et al. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism. 2014;63(6):735–745.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs. 2010;10(1):11–28.
   PubMed Web of Science ®Google Scholar
• Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002;20(4):303–328.
   PubMed Web of Science ®Google Scholar
• Quirk J, Thornton M, Kirkpatrick P. Rosuvastatin calcium. Nat Rev Drug Discov. 2003;2:769–770.
   PubMed Web of Science ®Google Scholar
• Sudhop T, Lu¨tjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943–1948.
   PubMed Web of Science ®Google Scholar
• van Heek M, Farley C, Compton DS, et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001;134:409–417.
   PubMed Web of Science ®Google Scholar
• Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. N Engl J Med. 2009;361:712–717.
   PubMed Web of Science ®Google Scholar
• Hammersley D, Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Ther Adv Chronic Dis. 2017;8(1):4–11.
   PubMed Web of Science ®Google Scholar
• Nakano T, Inoue I, Takenaka Y, et al. Ezetimibe Promotes Brush Border Membrane-to-Lumen Cholesterol Efflux in the SmallIntestine. PLoS One. 2016 Mar 29;11(3):e0152207. doi:10.1371/journal.pone.0152207.
   Google Scholar
• Knopp R, Bays H, Manion C, et al. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. Atheroscler Suppl. 2001;2:90.
   Google Scholar
• van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000;129:1748–1754.
   PubMed Web of Science ®Google Scholar
• Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active me-tabolites of SCH48461. J Pharmacol Exp Ther. 1997;283:157–163.
   PubMed Web of Science ®Google Scholar
• Farnier M. Ezetimibe in hypercholesterolemia. Int J Clin Pract. 2002;56(8):611–614.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009;103(3):369–374.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93:1487–1494.
   PubMed Web of Science ®Google Scholar
• Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251–261.
   PubMed Web of Science ®Google Scholar
• Pearson T, Ballantyne C, Sisk C, et al. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007;99:1706–1713.
   PubMed Web of Science ®Google Scholar
• Tsunoda T, Nozue T, Yamada M, et al. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract. 2013;100:46–52.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004;20:1185–1195.
   PubMed Web of Science ®Google Scholar
• Bucci KK, Possidente CJ. Combination-drug products: benefit or burden to patients? Am J Health Syst Pharm. 2006;63:1654–1655.
   PubMed Web of Science ®Google Scholar
• Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature. 2005;438:612–621.
   PubMed Web of Science ®Google Scholar
• Gylling H. Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int J Clin Pract. 2004;58:859–866.
   PubMed Web of Science ®Google Scholar
• Verschuren L, Radonjic M, Wielinga PY, et al. Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy. Pharmacogenet Genomics. 2012;22(12):837–845.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11:367–383.
   PubMed Web of Science ®Google Scholar
• Strilchuk L, Fogacci F, Cicero AFG. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Exp Opin Drug Saf. 2019;18(7):611–621.
   PubMed Web of Science ®Google Scholar
• Tibolla G, Norata GD, Artali R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis. 2011;21:835–843.
   PubMed Web of Science ®Google Scholar
• Seidah NG. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets. 2009;13:19–28.
   PubMed Web of Science ®Google Scholar
• Zhang J, Long M, Yu Y. The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina. J Thorac Dis. 2017;9(5):1226–1233.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Kim SH, Yoon YW, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROSE (Multicenter randomized study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016;34(5):371–382.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Weiss R, Moccetti T, et al. for the EXPLORER study investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (Results from the EXPLORER study). Am J Cardiol. 2007;99:673–680.
   PubMed Web of Science ®Google Scholar
• Hong SJ, Jeong HS, Ahn JC, et al. A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong rosuvastatin & ezetimibe for hypercholesterolemia) randomized controlled trial. Clin Ther. 2018;40(2):226–241.e4.
   PubMed Web of Science ®Google Scholar
• Ren Y, Zhu H, Fan Z, et al. Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Exp Ther Med. 2017;14(5):4942–4950.
   PubMed Web of Science ®Google Scholar
• Kouvelos G, Arnaoutoglou E, Matsagkas M, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. J Cardiovasc Pharmacol Ther. 2013;18:5–12.
   PubMed Web of Science ®Google Scholar
• Yang Y-J, Lee S-H, Kim BS, et al. Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk. Clin Ther. 2017;39(1):107–117.
   PubMed Web of Science ®Google Scholar
• Kim W, Yoon YE, Shin S-H, et al. Efficacy and safety of ezetimibe and rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2018;40(6):993–1013.
   PubMed Web of Science ®Google Scholar
• Masuda J, Tanigawa T, Yamada T, et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J. 2015;56(3):278–285.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao X, Li L, et al. Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart Lung Circ. 2016;25(5):459–465.
   PubMed Web of Science ®Google Scholar
• Ambegaonkar BM, Tipping D, Polis AB, et al. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis. 2014;237(2):829–837.
   PubMed Web of Science ®Google Scholar
• Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE study). Am J Cardiol. 2011;108:523–530.
   PubMed Web of Science ®Google Scholar
• Torimoto K, Okada Y, Mori H, et al. Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013;12:137.
   PubMed Web of Science ®Google Scholar
• Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582–587.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005;149(3):464–473.
   PubMed Web of Science ®Google Scholar
• Yamazaki D, Ishida M, Watanabe H, et al. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis. 2013;12:9.
   PubMed Web of Science ®Google Scholar
• Pesaro AE, Serrano CV Jr, Fernandes JL, et al. Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Int J Cardiol. 2012;158(3):400–404.
   PubMed Web of Science ®Google Scholar
• Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007;49(10):1035–1042.
   PubMed Web of Science ®Google Scholar
• Kurobe H, Aihara K, Higashida M, et al. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. J Atheroscler Thromb. 2011;18(12):1080–1089.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Raya JL, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study. Atherosclerosis. 2014;232:86–93.
   PubMed Web of Science ®Google Scholar
• Ravid Z, Bendayan M, Delvin E, et al. Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors. Am J Physiol Gastrointest Liver Physiol. 2008;295:G873–G885.
   PubMed Web of Science ®Google Scholar
• Hwang YC, Jun JE, Jeong IK, et al. Comparison of the efficacy of rosuvastatin monotherapy 20 mg with rosuvastatin 5 mg and Ezetimibe 10 mg combination therapy on lipid parameters in patients with type 2 diabetes mellitus. Diabetes Metab J. 2019;43:e2.
   Google Scholar
• Pilz S, Marz W. Free fatty acids as a cardiovascular risk factor. Clin Chem Lab Med. 2008;46:429–434.
   PubMed Web of Science ®Google Scholar
• Pilz S, Scharnagl H, Tiran B, et al. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J Clin Endocrinol Metab. 2006;91:2542–2547.
   PubMed Web of Science ®Google Scholar
• Djousse L, Benkeser D, Arnold A, et al. Plasma free fatty acids and risk of heart failure: the cardiovascular health study. Circ Heart Fail. 2013;6:964–969.
   PubMed Web of Science ®Google Scholar
• Klein D, Hurley LB, Quesenberry CP Jr., et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471–477.
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479–2486.
   PubMed Web of Science ®Google Scholar
• Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 2007;6:15.
   PubMed Web of Science ®Google Scholar
• Saeedi R, Johns K, Frohlich J, et al. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis. 2015;14:57.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Zhan S, Tang M, Liu F, et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11:CD012502.
   PubMedGoogle Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Landolfo M, Ventura F, et al. Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opin Pharmacother. 2019;20(10):1277–1288.
   PubMed Web of Science ®Google Scholar
• Bove M, Fogacci F, Cicero AFG. Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2017;13(10):1099–1104.
   PubMed Web of Science ®Google Scholar
• Bove M, Cicero AFG, Borghi C. Emerging drugs for the treatment of hypercholesterolemia. Expert Opin Emerg Drugs. 2019;24(1):63–69.
   PubMed Web of Science ®Google Scholar